1 in 5 Cancer Survivors Use CBD for Pain, Sleep and Distress

Photo by Cosmin Ursea via Unsplash.

A survivor mentions, almost in passing, that the CBD tincture she picked up at a gas station is the only thing that gets her to sleep before a scan. Her oncologist nods, doesn't ask a follow-up question, and moves on to the next item on the visit checklist. That interaction, or some version of it, is happening constantly right now across cancer clinics, and new research is finally putting numbers to something oncology has mostly handled through silence.

A study out of VCU Massey Comprehensive Cancer Center, paired with a growing stack of related research, puts a hard figure on what's been an open secret in oncology for years: roughly one in five cancer survivors is currently using CBD or cannabis to manage symptoms from their disease or its treatment. That's not a fringe wellness trend confined to a handful of outspoken patients. It's a routine, quiet behavior happening during active chemotherapy, during radiation, and well into survivorship, often with no mention of it in the medical chart at all.

What makes this moment notable isn't the usage rate itself so much as the gap sitting right next to it. Patients are, by and large, using these products on their own initiative, researching dosing on forums and product labels, and deciding what to try based on trial and error rather than clinical guidance. Their care teams, meanwhile, are only partway prepared to have that conversation. The new data doesn't just describe patient behavior -- it exposes a structural blind spot in how survivorship care is currently built.

What the Numbers Actually Show

Among cancer patients who use cannabis, sleep disturbances (60%) are the most commonly cited reason, followed by pain (51%), stress (44%), and nausea (33%).

The clearest numbers come from a VCU Massey Comprehensive Cancer Center survey led by Dr. Sunny Jung Kim, published in the Journal of Cancer Education, which polled 395 cancer survivors alongside 62 cancer care providers about cannabis use and attitudes. It's a rare study design because it captures both sides of the exam room table at once, rather than just asking patients what they're doing or just asking clinicians what they think is happening.

Separate data published in the Journal of Cancer Survivorship adds texture to the picture among patients still in active treatment: 17.4% reported being current cannabis users, 30.5% said they'd used it in the past but stopped, and 52.2% said they'd never used it at all. Roughly half of all patients, in other words, have at least tried it at some point during their cancer experience.

Among the 510 respondents in that same dataset who reported using cannabis at any point after diagnosis, the reasons cluster around a few specific complaints. Sixty percent cited sleep disturbances, 51% cited pain, 44% cited stress, and 33% cited nausea. Those four categories cover most of what makes cancer treatment miserable day to day, which likely explains why cannabis use shows up so consistently across different patient populations and cancer types.

A separate review in JNCI Cancer Spectrum focused specifically on CBD, rather than cannabis broadly, and found survivors reporting decreased pain in 21% of cases, decreased anxiety in 17%, and improved sleep in 15%. It's worth being precise about what these numbers represent: self-reported symptom relief, not clinical outcomes verified through trials, and nothing here constitutes an FDA-approved treatment claim for cancer or its symptoms. Patients feel better, or say they do. That's a meaningful data point, but it's a different category of evidence than a drug approval.

The Communication Gap Between Patients and Providers

Photo by Thirdman via Pexels.

Here's where the VCU Massey data gets genuinely interesting: 68.5% of survivors said they felt comfortable discussing cannabis use with their care team. Only 46.7% of providers said the same about discussing it with patients. That's more than a 20-point gap, and it flips the usual assumption that patients are the reluctant party in these conversations. In this case, it's clinicians who are more hesitant to bring it up.

The risk-awareness numbers cut the other direction. Providers were far more likely to identify cannabis-related risks -- interactions, dosing uncertainty, product inconsistency -- than survivors were, at 25% versus just 8.4%, a gap the study's authors flagged as statistically significant. So you've got a population of patients who are relatively comfortable discussing cannabis but under-informed about its risks, paired with a population of providers who understand the risks better but are less willing to initiate the conversation. That's about as clear a recipe for a communication breakdown as you could design on purpose.

Notably, broader attitudes toward medical cannabis were fairly similar between survivors and providers -- neither group is running some hidden anti-cannabis campaign against the other. The gap is procedural and behavioral, not ideological.

Kim's interest in this area reportedly grew out of a separate but related push in oncology: finding alternatives to long-term opioid use for cancer-related pain. As she put it, people are seeking different approaches to avoid or reduce long-term opioid use, and cannabis is one of the options patients are reaching for on their own, with or without a formal referral to try it.

Why This Matters for Chemo Brain and Long-Term Survivorship

Photo by Tara Winstead via Pexels.

A study out of UC Irvine, published in Cancer Letters in June 2026 and led by Shreya Madan alongside Acharya, pushes this conversation into territory well past pain and nausea: chemo brain, the cognitive fog that lingers for many patients long after treatment ends. The research examined whether CBD might play some role in addressing chemotherapy-related cognitive impairment, a symptom cluster that gets far less attention than physical side effects but can be just as disruptive to a survivor's return to work, driving, or daily decision-making.

The scale of who this affects is worth sitting with. There are an estimated 18.6 million people currently living as cancer survivors in the United States, and depending on the study population and how impairment is measured, somewhere between 35% and 70% of survivors experience some degree of cancer-therapy-related cognitive impairment. That's an enormous range of people dealing with memory lapses, slowed processing, or difficulty concentrating, sometimes for years after their last chemotherapy infusion.

This is where the CBD conversation stops being just about managing acute treatment side effects and becomes a long-term quality-of-life issue. Pain and nausea tend to fade as treatment ends. Cognitive changes don't necessarily follow the same timeline, and survivors often describe feeling unprepared for how long chemo brain sticks around, or how little their care team addresses it once active treatment wraps up.

It bears repeating that this research is early-stage. A single study examining CBD's potential mechanisms in cognitive impairment is a starting point for further investigation, not a green light to self-treat memory problems instead of getting them properly evaluated by a neurologist or oncologist.

What Survivors Should Know Before Trying CBD

Photo by CBD-Infos-com via Pixabay.

Anyone considering CBD for cancer-related symptoms is dealing with a legal landscape that shifts depending on where they live. Hemp-derived CBD is federally legal in the U.S. under certain conditions, but state rules vary, and internationally the legal status of both CBD and THC-containing cannabis products differs enormously by country. Products sold online aren't held to a consistent quality or testing standard the way prescription drugs are, which means the tincture that worked well for one survivor might be a completely different concentration, or contain different contaminants, than the bottle sitting on a shelf two states away.

The interaction risk deserves real attention. CBD is processed through liver enzyme pathways that also metabolize a wide range of chemotherapy drugs and other medications, meaning it has the potential to raise or lower how much of a drug ends up active in the bloodstream. Telling an oncologist about CBD use matters even if that provider seems unfamiliar with cannabis specifically -- the point isn't finding a cannabis expert, it's making sure the full medication picture is on record.

Dosing consistency is another practical concern. Prescription medications come with regulated, tested dosing. CBD products largely don't, and label claims don't always match lab results.

Anyone weighing this decision should ask specific questions before buying anything: has the product been third-party tested, what's the actual THC content, and could this interact with anything currently being taken for treatment or side effect management. And because cannabis and CBD laws differ by state and country, and can change, it's worth confirming current local rules before making any purchase or treatment decision.

Strip away the specific percentages and what's left is a fairly simple story: cancer patients have already decided, on their own, that cannabis and CBD are worth trying for symptoms that conventional treatment doesn't fully address. That decision isn't waiting on more clinical trials or FDA guidance. It's happening now, in homes and hospital rooms, often without anyone on the care team knowing about it.

The more urgent problem isn't whether CBD works as well as some survivors believe it does -- that's a legitimate open scientific question, and it deserves continued research. The more urgent problem is that a meaningful share of patients are managing chemotherapy drug interactions, dosing decisions, and product quality entirely on their own, without the benefit of a clinician who knows what they're taking. Closing that gap doesn't require resolving every efficacy question first. It just requires providers asking the question and patients feeling safe enough to answer honestly, which the data suggests is closer to happening than not.

With 18.6 million cancer survivors currently living in the U.S., and that number only growing as treatment outcomes improve, survivorship care is going to keep running into this same tension between what patients are quietly doing at home and what gets documented in a clinic visit. The oncology field doesn't need to have every answer about CBD's mechanisms to start treating the conversation as a routine, expected part of care -- the same way providers now ask about supplements, alcohol use, or exercise. Right now, that conversation is still optional in too many exam rooms, and survivors are filling the silence on their own.